Beacon Pharmaceuticals PLC

BEACONPHAR

BD0482BECON5

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 15/09/2024			5-day change	1st Jan Change
134.10 ^BDT	-2.12%		+17.73%	-45.27%

16/05	Beacon Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
13/02	Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2020

October 28, 2020 at 08:33 pm IST

Beacon Pharmaceuticals Ltd. Board of Directors has recommended 6% cash dividend for the year ended on June 30, 2020.

Latest news about Beacon Pharmaceuticals PLC

Beacon Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	16/05	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02	CI
Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary	30/01	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	24/01	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended June 30, 2023	05/12	CI
Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023	23/23/23	CI
Beacon Pharmaceuticals plc Appoints Mr. Ulfat Karim as the Director and Chief Operating Officer	13/23/13	CI
Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer	19/23/19	CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFO	11/23/11	CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as Director (Finance & Accounts)	11/23/11	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	04/23/04	CI
Beacon Pharmaceuticals Limited will Change its Name to Beacon Pharmaceuticals PLC	16/23/16	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	14/23/14	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022	22/22/22	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2022	22/22/22	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022	26/22/26	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	19/22/19	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	11/22/11	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2021	28/21/28	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021	20/21/20	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2021	29/21/29	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter Ended March 31, 2021	06/21/06	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended December 31, 2020	05/21/05	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2020	28/20/28	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter Ended March 31, 2020	23/20/23	CI

Chart Beacon Pharmaceuticals PLC

Duration

Period

More charts

Beacon Pharmaceuticals PLC, formerly Beacon Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract manufacturing and tool manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral and biotech. Its products include Favipiravir, Remdisivir INN, Meropenem, Bendamustine, Bleomycin Sulfate, Daunorubicin, Gemcitabine, Darbepoetin alfa and Filgrastim.

Employees

3,872

Sector

Pharmaceuticals

More about the company